UNSPSC 51131507: Darbepoetin alfa

This classification denotes a gnas gene with the molecular formula C800H1300N228O24S5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15UQ94PT4P, more generally known as darbepoetin alfa. European Medicines Agency schedules darbepoetin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12486MIG. The term DARBEPOETIN ALFA is an International Non-Proprietary Name or INN. Most nations schedule darbepoetin alfa under HS 30021095 and SITC 54163.

As of Q4 2014, DARBEPOETIN ALFA remains the US FDA Preferred Term for this commodity. Darbepoetin alfa bears US NLM identifiers UMLS ID C0937950 and NCI Concept Code C1878. SMILES: NONE.

UNSPSC 51131507 Darbepoetin alfa is a Commodity code identifying a specific pharmaceutical product — an erythropoiesis-stimulating agent used to treat anemia — yet the recent state and local procurement record shows no activity aligned with this code's nominal scope. The single recent opportunity posted under this code is a Sourcewell RFP #061626 issued May 12, 2026 (due June 16, 2026) for law enforcement equipment procurement, which bears no relationship to pharmaceutical procurement or darbepoetin alfa supply. This mismatch signals either a miscoding error in the opportunity record or a data-entry artifact; the code does not reflect active state and local demand for the pharmaceutical product it nominates.

The opportunity itself — a cooperative purchasing vehicle administered by Sourcewell, a Minnesota local government unit service cooperative — encompasses Franklin County, Grant County, Grays Harbor County, Chelan County, Yakima County, and numerous other jurisdictions and public entities throughout the United States and Canada, with eligibility extended to governmental agencies, higher education institutions, K-12 school districts, nonprofit organizations, and tribal governments. However, the law enforcement equipment focus of RFP #061626 provides no insight into actual procurement patterns or issuing bodies for darbepoetin alfa. Absent recent opportunities genuinely tied to pharmaceutical supply or anemia-treatment product procurement, this code shows no reliable signal of current state and local buying activity in its nominal category.